This article is more than 5 years old. Information may no longer be current.

CIBA Vision, Johnson & Johnson reach settlement over contact lenses

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ATLANTA — CIBA Vision has reached a global settlement agreement with Johnson & Johnson Vision Care regarding CIBA’s patent-protected silicone hydrogel contact lens technology, according to a press release from CIBA.

Under the agreement, Johnson & Johnson will continue to manufacture, market and sell its full line of silicone hydrogel contact lenses, including Acuvue Oasys, Acuvue Advance and 1 Day Acuvue TruEye, under a license from CIBA. The lenses can be sold worldwide, including in markets previously under restriction, the release said.

The settlement concludes ongoing litigation in the U.S. and in European countries, the release said. In 2005, CIBA Vision filed suit against Vistakon, a division of Johnson & Johnson, for allegedly infringing upon CIBA’s “Nicolson” patents, which cover CIBA’s Night & Day and O2Optix breathable contact lens technology, Primary Care Optometry News previously reported.

The terms and financial details of the settlement are confidential, Richard E. Weisbarth, OD, FAAO, CIBA Vision vice president of professional affairs, said in the release.